David L. Hoey, president and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.
Pablo Penaloza-MacMaster, PhD, assistant professor of microbiology and immunology, Feinberg College of Medicine, Northwestern University, Chicago.
Jasdave Chahal, PhD, co-founder and chief scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.
Vaxart news release: “Vaxart Announced Good Best-line Phase II clinical Study Information Demonstrating Safaety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate.”
Mark Herr, spokesperson, Vaxart Inc.
The Commonwealth Fund: “Two Years of U.S. COVID-19 Vaccines Have Prevented Millions of Hospitalizations and Deaths.”
The Lancet Infectious Ailments: “Global influence of the initially year of COVID-19 vaccination: a mathematical modelling study.”
CDC: COVID Information Tracker, “Needle Fears and Phobias—Find Methods to Handle.”
U.S. Specialty Formulations news release: “Research Demonstrates Advantages of Oral COVID-19 Vaccine.”
CanSino Biologics Inc. statement: “Inside Info.”
Coalition for Epidemic Preparedness Innovations: E mail statement News releases: “The Race to Future-Proof Coronavirus Vaccines.” “Coming in from the cold: needle-no cost patch technologies for mRNA vaccines aims to finish want for frozen storage and increase access.”
Executive Workplace of the President: “Statement of Administration Policy.”
Science: “Mosaic RBD nanoparticles shield against challenge by diverse sarbecoviruses in animal models.”
Caltech news release: “Nanoparticle Vaccine Protects Against a Spectrum of COVID-19-causing Variants and Associated Viruses.”
U.S. Government Accountability Workplace. “Operation Warp Speed.”
Bharat Biotech International Restricted news release: “Bharat biotech launches iNCOVACC: World’s 1st intranasal COVID vaccine for Principal series and Heterologous booster.”
The Lancet preprints: “Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-two Vaccine, Compared with Intramuscular Covaxin® in Healthier Adults: A Randomised, Open-Label, Phase three Clinical Trial.”
Cell: “Intranasal pediatric parainfluenza virus-vectored SARS-CoV-two vaccine is protective in monkeys.”
National Institute of Allergy and Infectious Ailments news release: “NIAID Concerns Additional Awards to Assistance Pan-Coronavirus Vaccine Improvement.”
CEPI news release: “CEPI and DIOSynVax companion in quest to create broadly protective Betacoronavirus vaccine.”
CDC: “Understanding How COVID-19 Vaccines Perform.”
Nature Immunology: “The T-cell immune response against SARS-CoV-two.”
National Institutes of Well being: “T cells shield against COVID-19 in absence of antibody response.”
PNAS: “Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-two viral variants.”
Cell Reports: “Pre-current immunity modulates responses to mRNA boosters.”
University of Minnesota Center for Infectious Illness Investigation and Policy: “Coronavirus Vaccines R&D Roadmap.”
NIH news release: “2NIAID Research Highlight COVID-ten Natal Vaccine Possible.”
U.S. Specialty Formulations news release: “Research demonstrates advantages of oral COVID-19 vaccine.”